Update on therapeutic targets for vitiligo therapy

VernacularTitle:白癜风靶向治疗的研究进展
Author: Yan LU ¹ ; Yifei FENG ; Jiawei LU ; Xuechen CAO
Author Information

1. 江苏省人民医院　南京医科大学第一附属医院皮肤科，南京　210029
Keywords: Vitiligo; JAK inhibitors; Targeted therapy; MiRNA; Treg
From: Chinese Journal of Medical Aesthetics and Cosmetology 2024;30(1):1-6
CountryChina
Language:Chinese
Abstract: Vitiligo is a dermatological condition of autoimmune origin, characterized by the acquired loss of pigmentation in the skin and mucous membranes. Inflammatory cytokines, including interferon (IFN)-γ, interleukin (IL)-17, tumor necrosis factor (TNF)-α, IL-6, IL-8, IL-21, IL-33, phosphodiester enzyme (PDE)-4, and transforming growth factor (TGF)-β, play a crucial role in the progression of vitiligo. Among these, the IFN-γ/chemokine ligand (CXCL) 10 axis is particularly significant. In recent times, the advent of targeted therapeutic approaches, focusing on modulating cytokines and their corresponding receptors implicated in the pathogenesis of vitiligo, has assumed paramount significance. JAK inhibitors and their combination therapy with phototherapy have been clinically proven to have promising therapeutic prospects. This review undertakes a comprehensive appraisal of the therapeutic efficacy and tailored drug selection pertaining to diverse biological agents employed in the management of vitiligo, aiming to provide valuable insights for clinical therapeutic decisions.